Lyvgen Biopharma, a China-based global biotech company, announced on Sunday that it has entered into collaboration with United States-based Bristol Myers Squibb for an open label, phase two, multicentre, randomised trial of LVGN7409 and docetaxel or nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC).
LVGN7409, a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.
Bristol Myers Squibb's nivolumab is a human monoclonal antibody that binds to the PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.
LVGN7409 is a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.
Bristol Myers Squibb's nivolumab, a human monoclonal antibody, binds to the PD-1 and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.
Docetaxel, an anti-tubulin chemotherapy agent, is utilised to treat various types of cancer, including non-small-cell lung cancer, breast cancer, head and neck cancer, stomach cancer, and prostate cancer.
According to the terms of the contract, Lyvgen is to sponsor the study and Bristol Myers Squibb is to provide nivolumab for the combination trial. Lyvgen will have the global commercial and development rights to LVGN7409.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study